NCT02991911 - A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

BIOLOGICAL

MEDI3726 Post-Chemo

Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting

BIOLOGICAL

MEDI3726 Pre-Chemo

Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting

BIOLOGICAL

MEDI3726 & Enzalutamide Combo

MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting

Trial Locations (5)

7000

Research Site, Chur

23502

Research Site, Norfolk

34232

Research Site, Sarasota

06519

Research Site, New Haven

SM2 5PT

Research Site, London